Medtronic (NYSE:MDT) had much to tout with its pipeline as it released Street-beating fourth-quarter results.
CEO Geoff Martha announced to analysts that FDA has granted the company’s much-anticipated Hugo robot an investigational device exemption approval.
Medtronic is preparing to commence its Expand Uro trial in the U.S. to study Hugo in urologic procedures, Martha said during today’s earnings call, transcribed by Seeking Alpha.
Meanwhile, renal denervation appears to be back as a promising treatment for hypertension. Medtronic expects to release its On Med pivotal trial results later this year, likely at the TCT Conference in November. Martha thinks the results are “likely to be one of the most highly anticipated events in medtech this year.”
CFO Karen Parkhill added: “Two of our largest opportunities are surgical robotics and renal denervation. We’re purposely making significant investments in them to ensur…